Commercial expansion, clinical validation, and next-generation technologies defined this week’s MedTech funding activity. Investors continued to back innovation, with funding spanning surgical robotics, cardiovascular care, ultrasound therapies, AI, and home diagnostics. Here’s who raised capital.
Tissium closes $68M financing for tissue reconstruction polymers
The funding comes as the company advances the commercialization of Coaptium Connect with Tissium Light, its FDA-authorized, sutureless solution for peripheral nerve repair, while continuing development of products for nerve repair, hernia repair, and cardiovascular applications.
Tissium plans to use the proceeds to support commercial expansion, clinical programs, pipeline development, and further advancement of its proprietary biomorphic polymer platform.
Co-Founder and CEO Christophe Bancel
Last week’s tracker: Nyxoah, Wise & more
CroíValve closes expanded Series B at $36M
The company has expanded its Series B financing to $36M, adding $20M in new funding to the $16M raised in 2024. The company also secured $7M in grant funding from the EIC and DTIF.
The funding will support expansion of the TANDEM II clinical study evaluating CroíValve’s Duo Adapt system for patients with severe symptomatic tricuspid regurgitation (TR).
Co-Founder and CEO Lucy O’Keeffe
Carvolix secures new €10M tranche, bringing total financing to €20M
The company has raised an additional €10M tranche, bringing total funding under its €30M financing programme to €20M. Carvolix will allocate proceeds primarily to its pipeline, including Tavipilot, Kalios, Artus, Artedrone, and Mitrapilot, while also repaying a bridge loan.
The new capital reflects continued support from existing strategic shareholders and is intended to support both commercialization and clinical development of its AI-driven cardiovascular and neurovascular technologies.
CEO Sébastien Ladet
Pulsenmore announces pricing of $7.5M Private Placement
The gross proceeds from the offering are expected to be approximately $7.5M, before deducting placement agent commissions and other estimated offering expenses.
The company intends to use the net proceeds from the offering for marketing and commercialization activities, working capital and other general corporate purposes.
CEO Elazar Sonnenschein
HistoSonics closes new financing with value reaching $3.75B
The company did not disclose the terms of the financing but said it brings its valuation to $3.75B. Reed Jobs and Yosemite joined the round, alongside several new strategic investors.
Proceeds are earmarked for continued commercial expansion, clinical development programs, additional regulatory initiatives and further advancement of pipeline applications.
Chair and CEO Mike Blue
